Scientists re-engineer Patient's own cells to hunt deadly cancers

This early-phase trial tested a new personalized therapy for advanced gastrointestinal and other cancers driven by a specific genetic flaw called RAS G12D. Researchers collected a patient's own immune cells, genetically modified them in a lab to recognize and attack cancer cells with this mutation, and then infused them back into the patient. The main goals were to see if this approach was safe and if it could cause tumors to shrink in patients who had run out of standard treatment options.